| Betterchem |

|
|
| FDA approval activities
for this prescription drug:
Femara (letrozole) Tablets, 2.5 mg, Novartis NDA 20-726/S8 1/17/03 1/23/03 1/23/03 Femara (letrozole) Tablets, Novartis NDA 20-726/S-006 1/10/01 1/16/01 1/16/01 7/12/01 Femara (letrozole) Tablets, Novartis NDA 20-726/S-005 2/26/03 3/10/03 3/11/03 Femara Indications: First-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. |
© 2007 Betterchem Corp.
|